- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed or refractory diffuse large B-cell lymphoma
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Glofitamab – July 2025
Glofitamab; Solution concentrate for I.V. infusion 2.5 mg in 2.5 mL, Solution concentrate for I.V. infusion 10 mg in 10 mL; Columvi®
Last updated
9 July 2025